These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3950582)

  • 81. INTERFERENCE BETWEEN VIRUSES IN TISSUE CULTURE.
    Lennette EH; Koprowski H
    J Exp Med; 1946 Feb; 83(3):195-219. PubMed ID: 19871525
    [TBL] [Abstract][Full Text] [Related]  

  • 82. THE VIRUS-NEUTRALIZING ACTION OF SERUM FROM MICE INFECTED WITH POLIOMYELITIS VIRUS.
    Brown GC; Francis T
    J Exp Med; 1945 Feb; 81(2):161-9. PubMed ID: 19871450
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Monoclonal antibody treats yellow fever.
    Crunkhorn S
    Nat Rev Drug Discov; 2023 May; 22(5):355. PubMed ID: 37020013
    [No Abstract]   [Full Text] [Related]  

  • 84. [Immunization of the guinea pig against the yellow fever virus by skin scarification].
    FAVAREL R
    Bull Soc Pathol Exot Filiales; 1945; 38():77-87. PubMed ID: 21005353
    [No Abstract]   [Full Text] [Related]  

  • 85. Protective mechanisms of nonneutralizing antiviral antibodies.
    Chandler TL; Yang A; Otero CE; Permar SR; Caddy SL
    PLoS Pathog; 2023 Oct; 19(10):e1011670. PubMed ID: 37796829
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Novel approaches for the rapid development of rationally designed arbovirus vaccines.
    van Bree JWM; Visser I; Duyvestyn JM; Aguilar-Bretones M; Marshall EM; van Hemert MJ; Pijlman GP; van Nierop GP; Kikkert M; Rockx BHG; Miesen P; Fros JJ
    One Health; 2023 Jun; 16():100565. PubMed ID: 37363258
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Flavivirus NS1 and Its Potential in Vaccine Development.
    Carpio KL; Barrett ADT
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34207516
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Tick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise.
    Kubinski M; Beicht J; Gerlach T; Volz A; Sutter G; Rimmelzwaan GF
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32806696
    [TBL] [Abstract][Full Text] [Related]  

  • 89. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
    Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Tick-Borne Encephalitis Virus Nonstructural Protein 1 IgG Enzyme-Linked Immunosorbent Assay for Differentiating Infection versus Vaccination Antibody Responses.
    Girl P; Bestehorn-Willmann M; Zange S; Borde JP; Dobler G; von Buttlar H
    J Clin Microbiol; 2020 Mar; 58(4):. PubMed ID: 31969423
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Toll-Like Receptors and RIG-I-Like Receptors Play Important Roles in Resisting Flavivirus.
    Guo HY; Zhang XC; Jia RY
    J Immunol Res; 2018; 2018():6106582. PubMed ID: 29888293
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Innate Immune Evasion Mediated by Flaviviridae Non-Structural Proteins.
    Chen S; Wu Z; Wang M; Cheng A
    Viruses; 2017 Oct; 9(10):. PubMed ID: 28991176
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease.
    Calvert AE; Dixon KL; Piper J; Bennett SL; Thibodeaux BA; Barrett AD; Roehrig JT; Blair CD
    Antiviral Res; 2016 Jul; 131():92-9. PubMed ID: 27126613
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine.
    Geltz JJ; Gershburg E; Halford WP
    PLoS One; 2015; 10(2):e0116091. PubMed ID: 25658852
    [TBL] [Abstract][Full Text] [Related]  

  • 95. CD8+ T cells complement antibodies in protecting against yellow fever virus.
    Bassi MR; Kongsgaard M; Steffensen MA; Fenger C; Rasmussen M; Skjødt K; Finsen B; Stryhn A; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2015 Feb; 194(3):1141-53. PubMed ID: 25539816
    [TBL] [Abstract][Full Text] [Related]  

  • 96. How to approach and treat viral infections in ICU patients.
    Kelesidis T; Mastoris I; Metsini A; Tsiodras S
    BMC Infect Dis; 2014 Nov; 14():321. PubMed ID: 25431007
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
    Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
    Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Biomarkers in Japanese encephalitis: a review.
    Kant Upadhyay R
    Biomed Res Int; 2013; 2013():591290. PubMed ID: 24455705
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Issues related to recent dengue vaccine development.
    Konishi E
    Trop Med Health; 2011 Dec; 39(4 Suppl):63-71. PubMed ID: 22500138
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.
    Vogt MR; Dowd KA; Engle M; Tesh RB; Johnson S; Pierson TC; Diamond MS
    J Virol; 2011 Nov; 85(22):11567-80. PubMed ID: 21917960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.